Compare RVYL & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | ASBP |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 6.8M |
| IPO Year | 2008 | N/A |
| Metric | RVYL | ASBP |
|---|---|---|
| Price | $7.81 | $5.93 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.1K | ★ 263.1K |
| Earning Date | 04-15-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,131,000.00 | N/A |
| Revenue This Year | $770.54 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $0.05 |
| 52 Week High | $8.55 | $7.05 |
| Indicator | RVYL | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 58.88 |
| Support Level | $5.00 | $0.21 |
| Resistance Level | $8.55 | $7.05 |
| Average True Range (ATR) | 0.65 | 0.94 |
| MACD | 0.11 | -0.15 |
| Stochastic Oscillator | 96.06 | 66.32 |
Ryvyl Inc is a financial technology company that provides payment acceptance and disbursement solutions, mainly enabling merchants to process credit card transactions through BIN sponsorship arrangements with acquiring banks and payment processors, where it operates as an intermediary performing functions such as merchant underwriting, onboarding, risk monitoring, and customer support. The company also offers its internally developed NEMS Core platform, which facilitates automated inbound and outbound disbursements through a modular workflow system.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.